What happens next in GLP-1 — and when.

What changed

272 changes recorded since monitoring began on 2026-08-21, of 6 different kinds. This is the page that cannot be reconstructed anywhere else: ClinicalTrials.gov and the FDA shortage database both overwrite a record when it changes, keeping no public history of what it used to say. A completion date moving out by two years, a phase 3 trial quietly changing status, a presentation flipping to discontinued — each is invisible the day after it happens unless something was watching. Each row below carries the previous value alongside the new one.

Six times a day we snapshot the registry and compare it to the previous one. When a company quietly pushes a reporting date back, halts a trial or resizes an enrollment, ClinicalTrials.gov shows the new value and says nothing about the old one. So we keep the old one. Changes marked lead are phase 3 movements of six months or more, or phase 3 halts.

Take the whole archive: changes.json or changes.csv, rebuilt with the site and documented in the JSON itself. Entries marked new are first sightings rather than changes, and previous is empty where this site never saw an earlier value. CC BY 4.0 — cite GLP-1 Briefing and use it for anything.

272
changes on record
8
lead-story changes
203
trials affected
38
days observed
DetectedChangeDrugTrialDetailPhase
2026-10-15Results date moved leadsemaglutideA Study of BGM0504 in Participants With Type 2 Diabetes
NCT06716216 · BrightGene Bio-Medical Technology Co., Ltd.
2026-03-20 → 2026-11-14 8 mo laterP3
2026-10-15Status changedsemaglutideA Study to Learn About Switching to a Monthly Study Medicine Called Berobenatide (PF-08653944) to Help Keep Weight Off in People With Overweight or Obesity
NCT07845500 · Pfizer
Not yet recruiting → RecruitingP3
2026-10-15Status changedsemaglutideA Study of BGM0504 in Participants With Type 2 Diabetes
NCT06716216 · BrightGene Bio-Medical Technology Co., Ltd.
Recruiting → Active, not recruitingP3
2026-10-15New trial registeredtirzepatidePROACT AYA: Preventing Overweight/Obesity-Associated Cardiotoxicity With Tirzepatide In Adolescent And Young Adult Cancer Survivors - A Phase 2 Single-Arm, Single-Center Feasibility Study
NCT07874828 · M.D. Anderson Cancer Center
Not yet recruiting, n=30P2
2026-10-14Status changedsemaglutideSemaglutide vs Sitagliptin
NCT05195944 · University Health Network, Toronto
Enrolling by invitation → Active, not recruitingP4
2026-10-14New trial registeredsemaglutideFutureShape Family
NCT07872904 · Signe Torekov
Not yet recruiting, n=400P4
2026-10-14Status changedaleniglipronAleniglipron Phase 2 Body Composition Study
NCT07169942 · Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics
Active, not recruiting → CompletedP2
2026-10-14Results date movedaleniglipronAleniglipron Phase 2 Body Composition Study
NCT07169942 · Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics
2026-08 → 2026-09-09 1 mo laterP2
2026-10-13Results date moved leadsemaglutideA Study of BGM0504 in Participants With Type 2 Diabetes in Indonesia
NCT07064486 · BrightGene Bio-Medical Technology Co., Ltd.
2026-07-31 → 2027-04-30 9 mo laterP3
2026-10-13Enrollment changedsemaglutideA Study of BGM0504 in Participants With Type 2 Diabetes in Indonesia
NCT07064486 · BrightGene Bio-Medical Technology Co., Ltd.
477 → 152 participantsP3
2026-10-13Results date movedsemaglutideSemaglutide for Helping Opioid Recovery
NCT06639464 · Brigham and Women's Hospital
2026-08-31 → 2027-09-01 13 mo laterP2
2026-10-13Status changedecnoglutideA Study of Weekly Oral Dose of Ecnoglutide (VRB-101) for Weight Maintenance in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities
NCT07553299 · Verdiva Bio Dev Limited
Active, not recruiting → TerminatedP2
2026-10-13Status changedsemaglutideA Study of BGM0504 in Participants With Type 2 Diabetes in Indonesia
NCT07064486 · BrightGene Bio-Medical Technology Co., Ltd.
Recruiting → Active, not recruitingP3
2026-10-13New trial registeredsemaglutideELITE: Deep Profiling and Algorithmic Polytherapy to Map Individual Response in Healthy Aging
NCT07871799 · Sheba Medical Center
Completed, n=31P2
2026-10-13New trial registeredsemaglutideA Neuropsychobiological Approach to Optimize Patient Selection for GLP-1-based Pharmacotherapy for Weight Management Across the Binge Eating Spectrum
NCT07870538 · Universitaire Ziekenhuizen KU Leuven
Recruiting, n=96P4
2026-10-13Status changedsemaglutideRapid and Simultaneous Initiation of Four Guideline-Directed CKD Therapies (RAPID-CKD)
NCT07547878 · Baylor Research Institute
Not yet recruiting → Enrolling by invitationP4
2026-10-13Status changedtirzepatideEfficacy, Safety, and Pharmacokinetics of Tirzepatide (LY3298176) Once Weekly Versus Placebo in Pediatric Participants 6 to Less Than 12 Years of Age Who Have Obesity (ADVANCE-SURMOUNT-KIDS)
NCT07817875 · Eli Lilly and Company
Not yet recruiting → RecruitingP3
2026-10-13Status changedtirzepatideA Study of BGM0504 in Participants With Obesity
NCT06911203 · BrightGene Bio-Medical Technology Co., Ltd.
Recruiting → CompletedP2
2026-10-13Results date movedtirzepatideA Study of BGM0504 in Participants With Obesity
NCT06911203 · BrightGene Bio-Medical Technology Co., Ltd.
2026-01-11 → 2026-01-14P2
2026-10-13Enrollment changedtirzepatideA Study of BGM0504 in Participants With Obesity
NCT06911203 · BrightGene Bio-Medical Technology Co., Ltd.
90 → 96 participantsP2
2026-10-13Status changedtirzepatideSubcutaneous Tirzepatide Once-weekly in Patients With Obesity and Knee Osteoarthritis (STOP KNEE-OA)
NCT06191848 · University of Melbourne
Recruiting → Active, not recruitingP4
2026-10-13Status changedmazdutideEffect of Mazdutide on Coronary Plaque in Patients With Coronary Atherosclerosis and Overweight or Obesity
NCT07657676 · China National Center for Cardiovascular Diseases
Not yet recruiting → RecruitingP4
2026-10-13Results date movedecnoglutideA Study of Weekly Oral Dose of Ecnoglutide (VRB-101) for Weight Maintenance in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities
NCT07553299 · Verdiva Bio Dev Limited
2026-11-30 → 2026-09-11 2 mo earlierP2
2026-10-13Enrollment changedecnoglutideA Study of Weekly Oral Dose of Ecnoglutide (VRB-101) for Weight Maintenance in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities
NCT07553299 · Verdiva Bio Dev Limited
120 → 8 participantsP2
2026-10-13New trial registeredmaridebart cafraglutideHome Self-administration of Maridebart Cafraglutide With Autoinjector in Adults Living With Obesity or Overweight
NCT07871409 · Amgen
Not yet recruiting, n=230P3
2026-10-09New trial registeredVK2735Oral VK2735 for Weight Management in Adults With Type 2 Diabetes Mellitus Phase 3 (SUNRISE 2)
NCT07868939 · Viking Therapeutics, Inc.
Not yet recruiting, n=560P3
2026-10-09New trial registeredVK2735Oral VK2735 for Weight Management Phase 3 (SUNRISE 1)
NCT07868835 · Viking Therapeutics, Inc.
Not yet recruiting, n=560P3
2026-10-09New trial registeredexenatide
· AMNEAL
2026-10-09New trial registeredexenatide
· AMNEAL
2026-10-09New trial registeredexenatide
· AMNEAL
2026-10-08New trial registeredsemaglutideMaridebart Cafraglutide Versus Semaglutide in Participants With Type 2 Diabetes
NCT07866066 · Amgen
Not yet recruiting, n=1,300P3
2026-10-07Status changedsemaglutideSemaglutide in Women With Polycystic Ovary Syndrome and Obesity
NCT06896981 · Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh
Recruiting → CompletedP2/P3
2026-10-07Enrollment changedsemaglutideSemaglutide in Women With Polycystic Ovary Syndrome and Obesity
NCT06896981 · Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh
30 → 31 participantsP2/P3
2026-10-07Enrollment changedsemaglutideA Research Study on How Well Semaglutide Helps Children and Teenagers With Excess Body Weight Lose Weight
NCT05726227 · Novo Nordisk A/S
210 → 212 participantsP3
2026-10-07Status changedpetrelintideA Phase III Study to Evaluate the Efficacy and Safety of Petrelintide in Participants With Overweight or Obesity and Established Cardiovascular Disease
NCT07843472 · Hoffmann-La Roche
Not yet recruiting → RecruitingP3
2026-10-07Status changedpetrelintideA Phase III Study to Evaluate the Efficacy and Safety of Petrelintide in Participants With Overweight or Obesity
NCT07843498 · Hoffmann-La Roche
Not yet recruiting → RecruitingP3
2026-10-07Status changedpetrelintideA Phase III Study to Evaluate the Efficacy and Safety of Petrelintide in Participants With Overweight or Obesity and Type 2 Diabetes
NCT07843485 · Hoffmann-La Roche
Not yet recruiting → RecruitingP3
2026-10-06Status changedsemaglutideEfficacy and Safety of Ribupatide Administered Once Weekly Compared With Semaglutide and Placebo in Participants Living With Obesity Who Do Not Have Diabetes
NCT07284979 · Kailera
Recruiting → Active, not recruitingP3
2026-10-06Enrollment changedsemaglutideEfficacy and Safety of Ribupatide Administered Once Weekly Compared With Semaglutide and Placebo in Participants Living With Obesity Who Do Not Have Diabetes
NCT07284979 · Kailera
1,200 → 1,270 participantsP3
2026-10-06Results date movedmaridebart cafraglutideMaridebart Cafraglutide Versus Placebo in Adult Participants With Obstructive Sleep Apnea on Positive Airway Pressure Therapy
NCT07225686 · Amgen
2027-09-03 → 2027-08-20 1 mo earlierP3
2026-10-05New trial registeredsemaglutideThe Chronic Kidney Disease Adaptive Platform Trial Investigating Various Agents for Therapeutic Effect
NCT06058585 · The George Institute
Recruiting, n=2,000P3
2026-10-05Results date movedsemaglutideWeight-loss Drug for Fertility-Sparing Treatment of Atypical Hyperplasia and Low-grade Cancer of the Endometrium
NCT06073184 · GynOncTrials
2027-02 → 2029-02 24 mo laterP2
2026-10-05New trial registeredsemaglutideImmediate Versus Criterion-triggered Semaglutide for Suboptimal Clinical Response One Year After Primary Metabolic and Bariatric Surgery
NCT07859189 · General Committee of Teaching Hospitals and Institutes, Egypt
Not yet recruiting, n=100P4
2026-10-05New trial registeredsemaglutideTapered Versus Abrupt Discontinuation of Semaglutide After Treatment of Recurrent Weight Gain or Suboptimal Response Following Metabolic and Bariatric Surgery
NCT07859176 · General Committee of Teaching Hospitals and Institutes, Egypt
Not yet recruiting, n=100P4
2026-10-05New trial registeredsemaglutideSemaglutide Before Primary Metabolic and Bariatric Surgery in Patients With BMI 60 kg/m² or Higher
NCT07859137 · General Committee of Teaching Hospitals and Institutes, Egypt
Not yet recruiting, n=100P4
2026-10-05New trial registeredsemaglutideSemaglutide Given Before and After Conversion of Sleeve Gastrectomy to Roux-en-Y Gastric Bypass for Recurrent Weight Gain
NCT07859163 · General Committee of Teaching Hospitals and Institutes, Egypt
Not yet recruiting, n=100P4
2026-10-05New trial registeredsemaglutideSemaglutide 2.4 mg Once Weekly for Recurrent Weight Gain After Metabolic and Bariatric Surgery (RESURGE)
NCT07859150 · General Committee of Teaching Hospitals and Institutes, Egypt
Not yet recruiting, n=104P4
2026-10-05New trial registeredsemaglutidePatient-centred Intervention With Virtual Support for Obesity and Kidney Transplant Access
NCT07858331 · Kristin Clemens
Not yet recruiting, n=880P4
2026-10-05Status changedsemaglutideWeight-loss Drug for Fertility-Sparing Treatment of Atypical Hyperplasia and Low-grade Cancer of the Endometrium
NCT06073184 · GynOncTrials
Not yet recruiting → RecruitingP2
2026-10-02Results date movedtirzepatideGLP-1s to Enhance Lasting Optimal Weight
NCT06861439 · Wake Forest University Health Sciences
2026-10-30 → 2027-10-30 12 mo laterP4
2026-10-02New trial registeredsemaglutideSYNCHRONIZE®-START- A Study to Test Whether Survodutide Helps People Living With Overweight or Obesity Who do Not Have Diabetes to Lose Weight
NCT07855900 · Boehringer Ingelheim
Not yet recruiting, n=350P3
2026-10-02Status changedorforglipronA Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Osteoarthritis (OA) of the Knee
NCT07153471 · Eli Lilly and Company
Recruiting → Active, not recruitingP3
2026-10-01Results date movedsemaglutideA Study to Compare Different Doses of RO7795081 With Placebo or Semaglutide in People With Type 2 Diabetes
NCT07112872 · Hoffmann-La Roche
2026-11-27 → 2028-02-05 15 mo laterP2
2026-10-01Results date movedsemaglutideDUTCH Weight Control in Atrial Fibrillation Study
NCT06184633 · Rijnstate Hospital
2026-05-01 → 2027-04-10 11 mo laterP4
2026-10-01Enrollment changedtirzepatideTirzepatide in Thrombectomy-Treated Acute Ischemic Stroke: A Randomized Trial
NCT07734792 · yifang zhu
430 → 726 participantsP2/P3
2026-10-01Results date movedsemaglutideGlucagon-Like Peptide-1 Receptor Agonist in the Treatment of Adult, Obesity-related, Symptomatic Asthma (GATA-3)
NCT05254314 · Vanderbilt University Medical Center
2026-09-30 → 2026-09-28P2
2026-10-01Enrollment changedsemaglutideA Study to Compare Different Doses of RO7795081 With Placebo or Semaglutide in People With Type 2 Diabetes
NCT07112872 · Hoffmann-La Roche
240 → 330 participantsP2
2026-10-01Status changedsemaglutideDUTCH Weight Control in Atrial Fibrillation Study
NCT06184633 · Rijnstate Hospital
Recruiting → Active, not recruitingP4
2026-10-01Status changedsemaglutideSemaglutide 2.4mg for Low Responders After Bariatric Surgery
NCT06287307 · Zuyderland Medisch Centrum
Not yet recruiting → UnknownP4
2026-09-30New trial registeredsurvodutideELEVATE-LIVER: A Study to Test Whether Survodutide Helps Improve Heart Structure and Function in People With Overweight or Obesity and Fatty Liver Disease
NCT07850063 · Boehringer Ingelheim
Not yet recruiting, n=600P3
2026-09-30New trial registeredsurvodutideSYNCHRONIZE®-HERA: A Study to Test Whether Survodutide Helps Women Who Are Living With Overweight or Obesity and Are Going Through or Have Finished Menopause, to Lose Weight
NCT07850050 · Boehringer Ingelheim
Not yet recruiting, n=600P3
2026-09-30Status changedsemaglutideDoes GLP-1RA Prevent Deterioration of Metabolic State in Prediabetic and Diabetic Patients Treated With Antipsychotic Medication?
NCT04892199 · Anders Fink-Jensen, MD, DMSci
Active, not recruiting → UnknownP4
2026-09-30New trial registeredsemaglutideSequential Therapy Anti-obesitY Medication With Muscle Preservation for Weight Loss and MaintEnance: A PragmAtic Randomized CoNtrolled Trial (STAY-LEAN Trial)
NCT06854614 · The Cleveland Clinic
Active, not recruiting, n=150P4
2026-09-30Status changedsemaglutideResearch Study on How People With Type 2 Diabetes Tolerate Switching From Semaglutide to Cagrisema
NCT07817251 · Novo Nordisk A/S
Not yet recruiting → RecruitingP3
2026-09-29New trial registeredsemaglutideA Study to Learn About Switching to a Monthly Study Medicine Called Berobenatide (PF-08653944) to Help Keep Weight Off in People With Overweight or Obesity
NCT07845500 · Pfizer
Not yet recruiting, n=660P3
2026-09-29New trial registeredsemaglutideSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years
NCT07845994 · University Hospital, Angers
Not yet recruiting, n=50P3
2026-09-29Enrollment changedsemaglutidePhase 2a Placebo-Controlled Study of VTX3232 Alone or in Combination With Semaglutide in Obesity
NCT06771115 · Zomagen Biosciences Ltd.
176 → 175 participantsP2
2026-09-29Status changedsemaglutideA Study to Assess the Efficacy, Safety and Tolerability of AT673 Co-administered With Semaglutide in Adult Participants With Type 2 Diabetes (T2D) and Overweight or Obesity
NCT07724340 · Antag Therapeutics
Recruiting → Active, not recruitingP2
2026-09-29New trial registeredtirzepatideTirzepatide Versus Positive Airway Pressure for the Treatment of Obstructive Sleep Apnoea: A Randomised Comparative Effectiveness Trial
NCT07846865 · Woolcock Institute of Medical Research
Not yet recruiting, n=256P2/P3
2026-09-29Status changedtirzepatideA Study to Investigate Weight Management With LY3841136 and Tirzepatide (LY3298176), Alone or in Combination, in Adult Participants With Obesity or Overweight With Type 2 Diabetes
NCT06603571 · Eli Lilly and Company
Active, not recruiting → CompletedP2
2026-09-29Status changedmaridebart cafraglutideMaridebart Cafraglutide Versus Placebo in Adult Participants With Obstructive Sleep Apnea Not on Positive Airway Pressure (PAP) Therapy
NCT07226765 · Amgen
Recruiting → Active, not recruitingP3
2026-09-29Results date movedmaridebart cafraglutideMaridebart Cafraglutide Versus Placebo in Adult Participants With Obstructive Sleep Apnea Not on Positive Airway Pressure (PAP) Therapy
NCT07226765 · Amgen
2027-09-29 → 2027-08-30 1 mo earlierP3
2026-09-28New trial registeredpetrelintideA Phase III Study to Evaluate the Efficacy and Safety of Petrelintide in Participants With Overweight or Obesity and Established Cardiovascular Disease
NCT07843472 · Hoffmann-La Roche
Not yet recruiting, n=2,500P3
2026-09-28New trial registeredpetrelintideA Phase III Study to Evaluate the Efficacy and Safety of Petrelintide in Participants With Overweight or Obesity and Type 2 Diabetes
NCT07843485 · Hoffmann-La Roche
Not yet recruiting, n=600P3
2026-09-28New trial registeredpetrelintideA Phase III Study to Evaluate the Efficacy and Safety of Petrelintide in Participants With Overweight or Obesity
NCT07843498 · Hoffmann-La Roche
Not yet recruiting, n=3,900P3
2026-09-28Status changedsemaglutideA Research Study Investigating How Well the Medicine Zenagamtide Helps People With Excess Body Weight Lose Weight Compared to Semaglutide
NCT07668414 · Novo Nordisk A/S
Not yet recruiting → RecruitingP3
2026-09-28Results date movedsemaglutideEffect of Retatrutide Compared With Semaglutide in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin With or Without SGLT2 Inhibitor (TRANSCEND-T2D-2)
NCT06260722 · Eli Lilly and Company
2026-08 → 2026-08-27P3
2026-09-28Status changedtirzepatideTirzepatide for Obesity and Meth Use Disorder
NCT06745128 · University of Texas Southwestern Medical Center
Active, not recruiting → CompletedP2
2026-09-28Results date movedtirzepatideTirzepatide for Obesity and Meth Use Disorder
NCT06745128 · University of Texas Southwestern Medical Center
2026-03-31 → 2026-02-12 1 mo earlierP2
2026-09-28Enrollment changedtirzepatideTirzepatide for Obesity and Meth Use Disorder
NCT06745128 · University of Texas Southwestern Medical Center
45 → 35 participantsP2
2026-09-28Results date movedtirzepatideGLP-1s to Enhance Lasting Optimal Weight
NCT06861439 · Wake Forest University Health Sciences
2026-09-30 → 2026-10-30 1 mo laterP4
2026-09-28New trial registeredmazdutideA Study of HRS-4729 Injection in Participants With Type 2 Diabetes
NCT07843862 · Fujian Shengdi Pharmaceutical Co., Ltd.
Not yet recruiting, n=240P2
2026-09-28Status changedmaridebart cafraglutideA Trial to Evaluate Efficacy and Safety of Maridebart Cafraglutide in Adults Living With Elevated Liver Fat and Obesity or Overweight
NCT07441252 · Amgen
Recruiting → Active, not recruitingP2
2026-09-28Results date movedmaridebart cafraglutideA Trial to Evaluate Efficacy and Safety of Maridebart Cafraglutide in Adults Living With Elevated Liver Fat and Obesity or Overweight
NCT07441252 · Amgen
2027-09-29 → 2027-08-25 1 mo earlierP2
2026-09-28Removed from registrysemaglutideStudy to Assess the Effect and Safety of ALV-100 on Maintenance of Weight Loss
NCT07837973 · Alveus Therapeutics, Inc.
Last seen as RecruitingP2
2026-09-25Results date movedsemaglutideA Clinical Study Comparing Semaglutide Injection and Wegovy® for Weight Management in Obese Subjects
NCT06738979 · Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
2026-07 → 2026-03-07 4 mo earlierP3
2026-09-25Results date movedsemaglutideEffect of Itopride on Semaglutide Gastroparesis
NCT07254715 · Ain Shams University
2026-04 → 2026-07-30 3 mo laterP4
2026-09-25Status changedsemaglutideA Clinical Study Comparing Semaglutide Injection and Wegovy® for Weight Management in Obese Subjects
NCT06738979 · Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Not yet recruiting → CompletedP3
2026-09-25Status changedsemaglutideEffect of Itopride on Semaglutide Gastroparesis
NCT07254715 · Ain Shams University
Recruiting → CompletedP4
2026-09-24New trial registeredsemaglutideStudy to Assess the Effect and Safety of ALV-100 on Maintenance of Weight Loss
NCT07837973 · Alveus Therapeutics, Inc.
Recruiting, n=220P2
2026-09-23Results date movedmazdutidePre-hepatectomy Rehabilitation in Obese MASLD-Complicated Living Liver Donors With Mazdutide (PRIME)
NCT07718126 · West China Hospital
2028-08-31 → 2029-02-28 6 mo laterP4
2026-09-23New trial registeredsemaglutideA Study Comparing the Effects of BGM0504 Injection and Semaglutide Injection on Obese Subjects.
NCT07836140 · Second Affiliated Hospital of Soochow University
Completed, n=60P2
2026-09-23Status changedtirzepatideTirzepatide for Treatment of CCCA
NCT07734870 · Johns Hopkins University
Not yet recruiting → RecruitingP2
2026-09-23Status changedmazdutidePre-hepatectomy Rehabilitation in Obese MASLD-Complicated Living Liver Donors With Mazdutide (PRIME)
NCT07718126 · West China Hospital
Not yet recruiting → RecruitingP4
2026-09-23field_changedmazdutidePre-hepatectomy Rehabilitation in Obese MASLD-Complicated Living Liver Donors With Mazdutide (PRIME)
NCT07718126 · West China Hospital
P4
2026-09-23New trial registeredecnoglutideA Study of Ecnoglutide Injection in Overweight or Obese Chinese Adolescents
NCT07836270 · Hangzhou Sciwind Biosciences Co., Ltd.
Not yet recruiting, n=192P3
2026-09-22New trial registeredsemaglutideWeekly GLP-1 Receptor Agonists in Obese Individuals Without Diabetes
NCT07834398 · Zagazig University
Completed, n=150P3
2026-09-22Status changedorforglipronA Study of Orforglipron in Participants With Overweight at Risk of Development of Obesity-Related Complications or Progression to Class 1 Obesity
NCT07794579 · Eli Lilly and Company
Not yet recruiting → RecruitingP3
2026-09-22Status changedmazdutideA Study of IBI362 in Subjects With HFpEF or HFmrEF Combined With Obesity
NCT06862908 · Innovent Biologics (Suzhou) Co. Ltd.
Recruiting → Active, not recruitingP2
2026-09-21Results date movedsemaglutideSemaglutide for Post-Smoking Cessation Weight Management
NCT06173778 · The University of Texas Health Science Center, Houston
2026-07-01 → 2028-05-25 22 mo laterP2
2026-09-21Results date movedsemaglutideThe Effect of Oral Semaglutide on Bone Turnover in Patients With T2D: a Randomized Placebo-controlled Clinical Trial
NCT06050577 · Odense University Hospital
2026-01-15 → 2027-01-15 12 mo laterP2
2026-09-21Results date movedtirzepatideA Study to Investigate Effectiveness of Tirzepatide Following Initiation of Ixekizumab in Participants With Active Psoriatic Arthritis and Overweight or Obesity in Clinical Practice (TOGETHER AMPLIFY-PsA)
NCT06864026 · Eli Lilly and Company
2027-11 → 2027-08 3 mo earlierP4
2026-09-21New trial registeredsemaglutideComparing Different Medication Regimens to Maintaining Weight Loss Among Adults With Obesity Using GLP-1s
NCT07832084 · Jing Luo
Not yet recruiting, n=60P4
2026-09-21Status changedtirzepatideA Study to Investigate Effectiveness of Tirzepatide Following Initiation of Ixekizumab in Participants With Active Psoriatic Arthritis and Overweight or Obesity in Clinical Practice (TOGETHER AMPLIFY-PsA)
NCT06864026 · Eli Lilly and Company
Recruiting → Active, not recruitingP4
2026-09-21Results date movedliraglutideA Trial to Investigate the Safety and Efficacy of Intra-articular 4P004 Injection in Subjects With Knee Synovitis and Osteoarthritis
NCT07225829 · 4Moving Biotech
2026-08-28 → 2026-08-31P2
2026-09-21Status changedefinopegdutideA Clinical Study of Efinopegdutide in People With Compensated Cirrhosis Due to Steatohepatitis (MK-6024-017)
NCT06465186 · Merck Sharp & Dohme LLC
Active, not recruiting → CompletedP2
2026-09-21Results date movedefinopegdutideA Clinical Study of Efinopegdutide in People With Compensated Cirrhosis Due to Steatohepatitis (MK-6024-017)
NCT06465186 · Merck Sharp & Dohme LLC
2026-08-06 → 2026-08-03P2
2026-09-21Enrollment changedefinopegdutideA Clinical Study of Efinopegdutide in People With Compensated Cirrhosis Due to Steatohepatitis (MK-6024-017)
NCT06465186 · Merck Sharp & Dohme LLC
80 → 85 participantsP2
2026-09-21New trial registeredolatorepatideEfficacy and Safety of Olatorepatide Versus Placebo in Adults With Moderate to Severe Hidradenitis Suppurativa Living With Overweight or Obesity
NCT07830329 · Regeneron Pharmaceuticals
Not yet recruiting, n=300P2
2026-09-18New trial registeredtirzepatideEfficacy of Tirzepatide for Weight Management in Patients With Suboptimal Weight Loss After Bariatric Surgery: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial
NCT07829198 · Universidade do Porto
Not yet recruiting, n=70P3
2026-09-18Status changedmaridebart cafraglutideMaridebart Cafraglutide Versus Placebo in Adult Participants With Obstructive Sleep Apnea on Positive Airway Pressure Therapy
NCT07225686 · Amgen
Recruiting → Active, not recruitingP3
2026-09-18Results date movedmaridebart cafraglutideMaridebart Cafraglutide Versus Placebo in Adult Participants With Obstructive Sleep Apnea on Positive Airway Pressure Therapy
NCT07225686 · Amgen
2027-09-29 → 2027-09-03P3
2026-09-17Status changedsemaglutideStudy to Explore the Safety and Efficacy of NT-0796 as an Adjunct to Semaglutide in Participants With Obesity (RESOLVE-2)
NCT07220629 · Rezera (formerly NodThera Limited)
Active, not recruiting → CompletedP2
2026-09-17Results date movedsemaglutideGlucagon-Like Peptide-1 Receptor Agonist in the Treatment of Adult, Obesity-related, Symptomatic Asthma (GATA-3)
NCT05254314 · Vanderbilt University Medical Center
2026-09 → 2026-09-30P2
2026-09-17Status changedtirzepatideResistance Training to Prevent Muscle Loss During Treatment With Tirzepatide
NCT07777575 · Technical University of Munich
Not yet recruiting → RecruitingP4
2026-09-17New trial registeredtirzepatideRandomized Controlled Trial of Tirzepatide for Methamphetamine Use Disorder
NCT07825857 · University of Texas Southwestern Medical Center
Not yet recruiting, n=228P2
2026-09-17New trial registeredmazdutideMazdutide for Weight Management and Gout in Adults With Obesity
NCT07824895 · Hongwei Jiang
Not yet recruiting, n=30P4
2026-09-16Results date moved leadsemaglutideSemaglutide for the Prevention Of Post-Transplant Diabetes Mellitus
NCT06913023 · University Health Network, Toronto
2027-11-30 → 2029-06-30 19 mo laterP2/P3
2026-09-16Enrollment changedsemaglutideSemaglutide for the Prevention Of Post-Transplant Diabetes Mellitus
NCT06913023 · University Health Network, Toronto
74 → 37 participantsP2/P3
2026-09-16Status changedsemaglutideA Research Study Comparing Different Ways of Increasing the Dose of NNC0662-0419 in Participants With Obesity
NCT07639021 · Novo Nordisk A/S
Recruiting → Active, not recruitingP2
2026-09-16Results date movedsemaglutideA Research Study Comparing Different Ways of Increasing the Dose of NNC0662-0419 in Participants With Obesity
NCT07639021 · Novo Nordisk A/S
2027-07-12 → 2027-06-14 1 mo earlierP2
2026-09-16Enrollment changedsemaglutideA Research Study Comparing Different Ways of Increasing the Dose of NNC0662-0419 in Participants With Obesity
NCT07639021 · Novo Nordisk A/S
230 → 233 participantsP2
2026-09-15Results date moved leadsemaglutideSemaglutide for the Treatment of Glucose Intolerance in Women With Prior Gestational Diabetes
NCT05569772 · Universitaire Ziekenhuizen KU Leuven
2029-06 → 2030-03 9 mo laterP3
2026-09-15New trial registeredsemaglutideComparative Study of Different Weekly GLP-1 Receptor Agonists Among Diabetic and Non-Diabetic Patients: Clinical Trial
NCT07820111 · Zagazig University
Completed, n=159P3
2026-09-15New trial registeredsemaglutideSemaglutide, Weight Loss, and LNG-IUD for Conservative Treatment of Endometrial Atypical Hyperplasia and Grade 1 Endometrial Cancer
NCT07820358 · The Methodist Hospital Research Institute
Not yet recruiting, n=48P2
2026-09-14Results date movedsemaglutideA Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide
NCT06897475 · Eli Lilly and Company
2026-12 → 2027-05 5 mo laterP2
2026-09-14Results date movedsemaglutideGlucagon-like Peptide-1 Receptor Agonists for Endovascular Stroke Thrombectomy
NCT07511543 · Population Health Research Institute
2031-09-30 → 2028-10-31 35 mo earlierP2
2026-09-14Results date movedsemaglutideInvestigation of GLP1-Receptor Agonists in Men With Prostate Cancer Taking Androgen Deprivation Therapy
NCT06908694 · Hamilton Health Sciences Corporation
2026-07-31 → 2027-10-31 15 mo laterP4
2026-09-14Results date movedorforglipronA Master Protocol for Orforglipron in Participants With Obstructive Sleep Apnea and Obesity or Overweight
NCT06649045 · Eli Lilly and Company
2026-11 → 2026-07-21 4 mo earlierP3
2026-09-14Status changedsemaglutidePhase III Study of UBT251 Injection in Patients With Type 2 Diabetes With Inadequate Glycemic Control on Metformin ± Sulfonylurea/SGLT2 Inhibitor Therapy (UNIGUIDE-2)
NCT07653477 · The United Bio-Technology (Hengqin) Co., Ltd.
Not yet recruiting → RecruitingP3
2026-09-14New trial registeredsemaglutideResearch Study on How People With Type 2 Diabetes Tolerate Switching From Semaglutide to Cagrisema
NCT07817251 · Novo Nordisk A/S
Not yet recruiting, n=210P3
2026-09-14Enrollment changedsemaglutideA Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide
NCT06897475 · Eli Lilly and Company
240 → 200 participantsP2
2026-09-14Enrollment changedsemaglutideGlucagon-like Peptide-1 Receptor Agonists for Endovascular Stroke Thrombectomy
NCT07511543 · Population Health Research Institute
826 → 100 participantsP2
2026-09-14field_changedsemaglutideGlucagon-like Peptide-1 Receptor Agonists for Endovascular Stroke Thrombectomy
NCT07511543 · Population Health Research Institute
P2
2026-09-14New trial registeredsemaglutideOptimizing Albuminuria Treatment in CKD With Finerenone and Semaglutide
NCT07819227 · University Medical Center Groningen
Completed, n=41P2
2026-09-14Status changedsemaglutideInvestigation of GLP1-Receptor Agonists in Men With Prostate Cancer Taking Androgen Deprivation Therapy
NCT06908694 · Hamilton Health Sciences Corporation
Recruiting → Active, not recruitingP4
2026-09-14New trial registeredtirzepatideEfficacy, Safety, and Pharmacokinetics of Tirzepatide (LY3298176) Once Weekly Versus Placebo in Pediatric Participants 6 to Less Than 12 Years of Age Who Have Obesity (ADVANCE-SURMOUNT-KIDS)
NCT07817875 · Eli Lilly and Company
Not yet recruiting, n=150P3
2026-09-14Status changedorforglipronA Master Protocol for Orforglipron in Participants With Obstructive Sleep Apnea and Obesity or Overweight
NCT06649045 · Eli Lilly and Company
Active, not recruiting → CompletedP3
2026-09-14Enrollment changedorforglipronA Master Protocol for Orforglipron in Participants With Obstructive Sleep Apnea and Obesity or Overweight
NCT06649045 · Eli Lilly and Company
600 → 712 participantsP3
2026-09-11Status changedtirzepatideA Study of Tirzepatide (LY3298176) in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 Diabetes
NCT05536804 · Eli Lilly and Company
Active, not recruiting → CompletedP2
2026-09-11Results date movedtirzepatideA Study of Tirzepatide (LY3298176) in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 Diabetes
NCT05536804 · Eli Lilly and Company
2026-09 → 2026-07-06 2 mo earlierP2
2026-09-11Enrollment changedtirzepatideA Study of Tirzepatide (LY3298176) in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 Diabetes
NCT05536804 · Eli Lilly and Company
140 → 134 participantsP2
2026-09-10New trial registeredsemaglutide
· NOVO
2026-09-10Results date movedsemaglutideEvaluation Of Semaglutide in Adults With Cocaine Use Disorder With and Without HIV
NCT06691243 · University of Maryland, Baltimore
2026-07 → 2027-01 6 mo laterP2
2026-09-10Status changedsemaglutideEvaluation Of Semaglutide in Adults With Cocaine Use Disorder With and Without HIV
NCT06691243 · University of Maryland, Baltimore
Recruiting → Active, not recruitingP2
2026-09-10Status changedsemaglutideA Research Study to Investigate the Effects of CagriSema Compared to Placebo in People With Type 2 Diabetes and Painful Diabetic Peripheral Neuropathy
NCT06797869 · Novo Nordisk A/S
Active, not recruiting → CompletedP2
2026-09-10Results date movedsemaglutideA Research Study to Investigate the Effects of CagriSema Compared to Placebo in People With Type 2 Diabetes and Painful Diabetic Peripheral Neuropathy
NCT06797869 · Novo Nordisk A/S
2026-08-21 → 2026-06-26 2 mo earlierP2
2026-09-10New trial registeredsemaglutideA Study Evaluating Safety and Tolerability of Switching From Semaglutide to Zovaglutide in Adults With Obesity (HORIZON-SWITCH-SZ)
NCT07812597 · Beijing QL Biopharmaceutical Co.,Ltd
Not yet recruiting, n=210P2
2026-09-09Status changedsemaglutideA Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in Children and Adolescents With Type 2 Diabetes
NCT07282613 · Novo Nordisk A/S
Not yet recruiting → RecruitingP3
2026-09-09Results date movedtirzepatideA Study to Assess Efficacy, Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of RO7204239 in Combination With Tirzepatide in Participants With Obesity or Overweight With At Least One Weight-related Comorbidity
NCT06965413 · Hoffmann-La Roche
2026-08-22 → 2026-09-03 1 mo laterP2
2026-09-09Status changedpetrelintideEfficacy and Safety of Petrelintide in Participants With Overweight or Obesity and Type 2 Diabetes (ZUPREME 2)
NCT06926842 · Zealand Pharma
Active, not recruiting → CompletedP2
2026-09-08Results date movedsemaglutideSemaglutide for Smoking Cessation in Patients With Diabetes
NCT07059377 · Ottawa Heart Institute Research Corporation
2026-07 → 2026-12 5 mo laterP3
2026-09-04Status changedsemaglutideImpact of Pharmacogenetic-Guided Treatment on Type 2 Diabetes.
NCT06851962 · Fundación para la Investigación del Hospital Clínico de Valencia
Active, not recruiting → CompletedP4
2026-09-04Enrollment changedsemaglutideImpact of Pharmacogenetic-Guided Treatment on Type 2 Diabetes.
NCT06851962 · Fundación para la Investigación del Hospital Clínico de Valencia
504 → 92 participantsP4
2026-09-04Status changedsemaglutideProof-of-Concept Study Evaluating Total Body Weight, Physical Function & Safety of Enobosarm in Patients Treated With GLP-1 Receptor Agonist, for Weight Loss
NCT07446998 · Veru Inc.
Recruiting → Active, not recruitingP2
2026-09-04Enrollment changedsemaglutideProof-of-Concept Study Evaluating Total Body Weight, Physical Function & Safety of Enobosarm in Patients Treated With GLP-1 Receptor Agonist, for Weight Loss
NCT07446998 · Veru Inc.
200 → 239 participantsP2
2026-09-04Status changedsemaglutideA Research Study to Compare Two Different Versions of Injectable Cagrilintide and Placebo in People With Excess Body Weight
NCT07745504 · Novo Nordisk A/S
Not yet recruiting → RecruitingP3
2026-09-03field_changed leadtirzepatide
·
2026-09-03New trial registeredtirzepatide
· ELI LILLY AND CO
2026-09-03New trial registeredtirzepatide
· ELI LILLY AND CO
2026-09-03field_changedtirzepatide
·
2026-09-03field_changedtirzepatide
·
2026-09-03field_changedtirzepatide
·
2026-09-03Enrollment changedsemaglutideBariatric Surgery vs. Semaglutide vs. Tirzepatide
NCT06803888 · Ali Aminian
125 → 140 participantsP4
2026-09-03New trial registeredsemaglutidePhase 2 Clinical Study of MWN109 Tablets in Participants With Type 2 Diabetes Mellitus
NCT07801820 · Shanghai Minwei Biotechnology Co., Ltd
Recruiting, n=240P2
2026-09-02Results date movedsemaglutideEfficacy and Safety of Empagliflozin or Semaglutide in Overweight/Obese Patients With Type 1 Diabetes
NCT06762314 · Mostafa Bahaa
2027-09-20 → 2026-01-20 20 mo earlierP2
2026-09-02Status changedsemaglutideEfficacy and Safety of Empagliflozin or Semaglutide in Overweight/Obese Patients With Type 1 Diabetes
NCT06762314 · Mostafa Bahaa
Recruiting → CompletedP2
2026-09-02Enrollment changedsemaglutideEfficacy and Safety of Empagliflozin or Semaglutide in Overweight/Obese Patients With Type 1 Diabetes
NCT06762314 · Mostafa Bahaa
105 → 114 participantsP2
2026-09-02Status changedsemaglutideEffect of Oral Semaglutide on Epicardial and Pericoronary Adipose Tissues in Type 2 Diabetes After Myocardial Infarction
NCT06557811 · University of Sao Paulo General Hospital
Not yet recruiting → UnknownP4
2026-09-01New trial registeredsemaglutidePostpartum Semaglutide to Reduce Cardiometabolic Risk After Gestational Diabetes
NCT07797036 · University of Massachusetts, Worcester
Not yet recruiting, n=226P2/P3
2026-09-01Results date movedsemaglutideA Study to Test if Trevogrumab or Trevogrumab With Garetosmab When Taken With Semaglutide is Safe and How Well They Work in Adult Patients With Obesity for Weight Loss, Fat Loss, and Lean Mass Preservation
NCT06299098 · Regeneron Pharmaceuticals
2026-05-06 → 2026-06-16 1 mo laterP2
2026-09-01New trial registeredtirzepatideA Study of SYH2069 Injection in Participants With T2DM Not Controlled With Diet/Exercise Alone or Metformin
NCT07796477 · CSPC Ouyi Pharmaceutical Co., Ltd.
Not yet recruiting, n=240P2
2026-08-31New trial registeredorforglipronA Study of Orforglipron in Participants With Overweight at Risk of Development of Obesity-Related Complications or Progression to Class 1 Obesity
NCT07794579 · Eli Lilly and Company
Not yet recruiting, n=2,001P3
2026-08-31New trial registeredpemvidutidePhase 3 Study of the Efficacy, Safety, and Clinical Outcomes of Pemvidutide in MASH
NCT07795164 · Altimmune, Inc.
Recruiting, n=1,800P3
2026-08-31Status changedsemaglutideEarly Reinitiation of Semaglutide Post-Sleeve Gastrectomy in Youth: A Randomized Clinical Trial
NCT06934655 · Children's Hospital Los Angeles
Not yet recruiting → RecruitingP3
2026-08-31Status changedliraglutideA Trial Investigating the Efficacy and Safety of Insulin Degludec/Liraglutide Injection in Subjects With Type 2 Diabetes
NCT06559722 · Tonghua Dongbao Pharmaceutical Co.,Ltd
Not yet recruiting → UnknownP3
2026-08-31Status changedmazdutideA Study of IBI362 9 mg in Chinese Adults With Obesity
NCT06164873 · Innovent Biologics (Suzhou) Co. Ltd.
Active, not recruiting → UnknownP3
2026-08-31Status changedecnoglutideA Study of Econoglutide Injection in Obese Participants With Knee Osteoarthritis (KOA)
NCT07734311 · Hangzhou Sciwind Biosciences Co., Ltd.
Not yet recruiting → RecruitingP3
2026-08-28field_changedliraglutide
·
2026-08-28Results date movedsemaglutideGLP-1R Agonist Treatment for Opioid Use Disorder
NCT06548490 · Milton S. Hershey Medical Center
2027-04 → 2027-04-30P2
2026-08-28Status changedtirzepatideTirzepatide in Idiopathic Intracranial Hypertension Trial
NCT07191873 · Duke University
Not yet recruiting → RecruitingP4
2026-08-28Results date movedmazdutideEffect of Mazdutide on Coronary Plaque in Patients With Coronary Atherosclerosis and Overweight or Obesity
NCT07657676 · China National Center for Cardiovascular Diseases
2027-10-31 → 2027-12-31 2 mo laterP4
2026-08-27New trial registered leadtirzepatide
· ELI LILLY AND CO
2026-08-27New trial registered leadtirzepatide
· ELI LILLY AND CO
2026-08-27New trial registeredsemaglutide
· NOVO
2026-08-27Status changedtirzepatideGLP-1R Actions on Muscle and the Skeleton
NCT07154719 · Pennington Biomedical Research Center
Active, not recruiting → RecruitingP4
2026-08-27New trial registeredorforglipronA Study of Orforglipron (LY3502970) in Chinese Participants With Obesity or Overweight and Weight-Related Health Problems
NCT07790861 · Eli Lilly and Company
Not yet recruiting, n=192P3
2026-08-26New trial registered leadtirzepatide
· ELI LILLY AND CO
2026-08-26Results date movedtirzepatideA Study of Weight Loss Intervention With Tirzepatide and Progestin Intrauterine Device to Treat Endometrial Hyperplasia and Grade 1 Endometrial Cancer
NCT07349641 · National Cancer Institute (NCI)
2028-12-31 → 2029-10-31 10 mo laterP2
2026-08-25New trial registeredsemaglutideA Randomized Controlled Study of Dose-tapering Regimen of Semaglutide for Weight-Loss Maintenance in Adults With Overweight or Obesity
NCT07783854 · Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Not yet recruiting, n=72P4
2026-08-24Status changedtirzepatideIncretin Therapies in Obesity-related HFpEF
NCT07554638 · Columbia University
Not yet recruiting → RecruitingP4
2026-08-24New trial registeredmazdutideMazdutide Plus LNG-IUS for Fertility-Sparing Treatment of AEH or Early Endometrial Cancer
NCT07781150 · Tongji Hospital
Not yet recruiting, n=128P2
2026-08-24Status changedmaridebart cafraglutideExtension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-2-EXTENSION)
NCT07684144 · Amgen
Not yet recruiting → RecruitingP3
2026-08-21New trial registeredlixisenatideiGlarLixi vs IDegAsp in Chinese Participants After OAD(s)
NCT05413369 · Sanofi
Completed, n=582P3
2026-08-21New trial registeredlixisenatideEfficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination Versus Insulin Glargine in Patients With Type 2 Diabetes
NCT02058160 · Sanofi
Completed, n=736P3
2026-08-21New trial registeredlixisenatideEfficacy and Safety of Insulin Glargine/ Lixisenatide Fixed Ratio Combination Compared to Insulin Glargine Alone and Lixisenatide Alone on Top of Metformin in Patients With T2DM
NCT02058147 · Sanofi
Completed, n=1,170P3
2026-08-21New trial registeredlixisenatideEvaluation of Cardiovascular Outcomes in Patients With Type 2 Diabetes After Acute Coronary Syndrome During Treatment With AVE0010 (Lixisenatide)
NCT01147250 · Sanofi
Completed, n=6,068P3
2026-08-21New trial registeredlixisenatideEfficacy and Safety of LixiLan Versus Insulin Glargine Alone Both With Metformin in Japanese With Type 2 Diabetes Mellitus Inadequately Controlled on Basal Insulin and Oral Antidiabetic Drugs
NCT02752412 · Sanofi
Completed, n=513P3
2026-08-21New trial registeredlixisenatideGLP-1 Receptor Agonist Lixisenatide (Morning or Evening) in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Metformin
NCT00712673 · Sanofi
Completed, n=680P3
2026-08-21New trial registeredlixisenatideEfficacy and Safety of Lixisenatide Versus Insulin Glulisine on Top of Insulin Glargine With or Without Metformin in Type 2 Diabetic Patients
NCT01768559 · Sanofi
Completed, n=894P3
2026-08-21New trial registeredlixisenatideEvaluation of Insulin Glargine/Lixisenatide Fixed Ratio Combination in Patients With Type 2 Diabetes Insufficiently Controlled With Oral Antidiabetic Drug(s)
NCT03798054 · Sanofi
Completed, n=878P3
2026-08-21New trial registeredlixisenatideGLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Sulfonylurea
NCT00713830 · Sanofi
Completed, n=859P3
2026-08-21New trial registeredlixisenatideEfficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination (LixiLan) to Insulin Glargine Alone on Top of Oral Anti-diabetic Drugs (OADs) With Type 2 Diabetes in Japan
NCT02752828 · Sanofi
Completed, n=521P3
2026-08-21New trial registeredaleniglipronA Study of Aleniglipron in Adults With Obesity or Overweight and Type 2 Diabetes Mellitus (ACCOMPLISH-2)
NCT07654374 · Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics
Recruiting, n=1,100P3
2026-08-21New trial registeredaleniglipronEfficacy and Safety of Aleniglipron in Participants With Obesity or Overweight With a Weight-Related Comorbidity (ACCOMPLISH-1)
NCT07654361 · Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics
Recruiting, n=3,600P3
2026-08-21New trial registeredalbiglutideA Study to Determine the Safety and Efficacy of Albiglutide in Subjects With Type 2 Diabetes
NCT00839527 · GlaxoSmithKline
Completed, n=685P3
2026-08-21New trial registeredalbiglutideA Study to Determine the Safety and Efficacy of Albiglutide Administered in Combination With Insulin Glargine
NCT00976391 · GlaxoSmithKline
Completed, n=586P3
2026-08-21New trial registeredalbiglutideA Study of the Efficacy and Safety of Albiglutide in Subjects With Type 2 Diabetes With Renal Impairment.
NCT01098539 · GlaxoSmithKline
Completed, n=507P3
2026-08-21New trial registeredalbiglutideA Study to Determine the Safety and Efficacy of Albiglutide in Patients With Type 2 Diabetes
NCT00838916 · GlaxoSmithKline
Completed, n=779P3
2026-08-21New trial registeredalbiglutideSafety and Efficacy of Albiglutide + Insulin Glargine Versus Insulin Lispro + Insulin Glargine Subjects With Type 2 Diabetes Mellitus
NCT02229227 · GlaxoSmithKline
Completed, n=814P3
2026-08-21New trial registeredalbiglutideEfficacy and Safety of Albiglutide in Treatment of Type 2 Diabetes
NCT00838903 · GlaxoSmithKline
Completed, n=1,049P3
2026-08-21New trial registeredlixisenatideLixisenatide-The Effects on Glucose and Lipid Metabolism in Type 2 Diabetes
NCT02049034 · University of Surrey
Completed, n=8P4
2026-08-21New trial registeredlixisenatideRegimen Transition After Short-Term Intensive Insulin Therapy in Type 2 Diabetes
NCT07173712 · Yanbing Li
Not yet recruiting, n=324P4
2026-08-21New trial registeredlixisenatideSafety and Tolerability of Lixisenatide in Combination With Oral Anti-Diabetic Treatment in Patients With Type 2 Diabetes
NCT01940965 · Sanofi
Completed, n=294P3
2026-08-21New trial registeredlixisenatideComparison of the Efficacy and Safety of Insulin Glargine/Lixisenatide Fixed Ratio Combination to Insulin Glargine in Patients With Type 2 Diabetes Insufficiently Controlled on Basal Insulin
NCT03798080 · Sanofi
Completed, n=426P3
2026-08-21New trial registeredlixisenatideEfficacy and Safety of Lixisenatide Versus Placebo on Top of Basal Insulin and/or Oral Antidiabetic Treatment in Older Type 2 Diabetic Patients
NCT01798706 · Sanofi
Completed, n=350P3
2026-08-21New trial registeredlixisenatideEfficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination (LixiLan) to Lixisenatide on Top of Oral Anti-diabetic Drugs (OADs) With Type 2 Diabetes in Japan
NCT02749890 · Sanofi
Completed, n=321P3
2026-08-21New trial registeredlixisenatideEfficacy and Safety of Soliqua Versus Lantus in Ethnically/Racially Diverse Patients With Type 2 Diabetes Mellitus Inadequately Controlled on Basal Insulin and Oral Antidiabetic Agents
NCT03434119 · Sanofi
Terminated, n=241P3
2026-08-21New trial registeredlixisenatideEvaluation of the Efficacy and Safety of GLP-1 Receptor Agonist Therapy In Steroid-Induced Diabetes
NCT07117240 · Medical University of Warsaw
Enrolling by invitation, n=100P4
2026-08-21New trial registeredlixisenatideImpact of Combined of Lantus(Insulin Glargine) and Lyxumia (Lixisenatide) on Insulin Secretion and Gastric Emptying
NCT01910194 · Profil Institut für Stoffwechselforschung GmbH
Completed, n=39P2
2026-08-21New trial registeredlixisenatideStudy Comparing the Efficacy and Safety of Insulin Glargine (Basal Insulin)/Lixisenatide (GLP-1 Receptor Agonist) Combination (Soliqua™) in Patients With Type 2 Diabetes Mellitus (T2DM)
NCT03767543 · Sanofi
Completed, n=265P3
2026-08-21New trial registeredlixisenatideThe Effect of Lixisenatide on the Effect of Pituitary Hormones
NCT05804513 · University of Tartu
Unknown, n=10P4
2026-08-21New trial registeredlixisenatideGLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Basal Insulin
NCT00715624 · Sanofi
Completed, n=496P3
2026-08-21New trial registeredlixisenatideStudy to Evaluate the Effect of Lixisenatide in Patient With Parkinson's Disease
NCT03439943 · University Hospital, Toulouse
Completed, n=156P2
2026-08-21New trial registeredlixisenatideGLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation in Monotherapy (GETGOAL-MONO Japan LTS)
NCT00905255 · Sanofi
Completed, n=69P3
2026-08-21New trial registeredlixisenatideThe Effect of Soliqua on Glucose Variability in Type 2 Patients Among South Asians
NCT03819790 · LMC Diabetes & Endocrinology Ltd.
Completed, n=119P4
2026-08-21New trial registeredlixisenatideEvaluation of Lixisenatide Efficacy in Diabetes Mellitus Type 2 With Failure of Other GLP-1 Analog
NCT02767596 · Laniado Hospital
Terminated, n=2P4
2026-08-21New trial registeredlixisenatideSafety And Tolerability Of Lixisenatide In Monotherapy In Patients With Type 2 Diabetes
NCT01960179 · Sanofi
Completed, n=361P3
2026-08-21New trial registeredlixisenatideSafety Assessment of Lyxumia (Lixisenatide) and Sulfonylurea as Add-on Treatment to Basal Insulin in Uncontrolled Patients With Type 2 Diabetes Mellitus Who Elect to Fast During Ramadan
NCT02941367 · Sanofi
Completed, n=184P4
2026-08-21New trial registeredlixisenatideGLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Pioglitazone
NCT00763815 · Sanofi
Completed, n=484P3
2026-08-21New trial registeredlixisenatideStudy on Lixisenatide and Counterregulation to Hypoglycemia
NCT02020629 · Lund University
Completed, n=18P4
2026-08-21New trial registeredlixisenatideGLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation in Monotherapy
NCT00688701 · Sanofi
Completed, n=361P3
2026-08-21New trial registeredlixisenatideEffects of Insulin Glargine and Lixisenatide on the Brain
NCT03881995 · University Hospital Tuebingen
Terminated, n=1P4
2026-08-21New trial registeredlixisenatideEfficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination Versus Insulin Glargine in Patients With Type 2 Diabetes (LixiLan-India)
NCT03529123 · Sanofi
Completed, n=247P3
2026-08-21New trial registeredlixisenatideEfficacy and Safety of Lixisenatide in Patients With Type 2 Diabetes Mellitus Insufficiently Controlled by Metformin
NCT01169779 · Sanofi
Completed, n=391P3
2026-08-21New trial registeredlixisenatide24-week Study Comparing Lixisenatide to Sitagliptin as add-on to Metformin in Obese Type 2 Diabetic Patients Younger Than 50 Years
NCT00976937 · Sanofi
Completed, n=319P3
2026-08-21New trial registeredlixisenatide24-week Treatment With Lixisenatide in Type 2 Diabetes Insufficiently Controlled With Metformin and Insulin Glargine
NCT00975286 · Sanofi
Completed, n=446P3
2026-08-21New trial registeredlixisenatideEffect of Soliqua 100/33 on Time in Range From Continuous Glucose Monitoring in Insulin-naive Patients With Very Uncontrolled Type 2 Diabetes Mellitus
NCT05114590 · Sanofi
Completed, n=124P4
2026-08-21New trial registeredlixisenatideiGlarLixi CGM Study in Chinese T2D Individuals After OADs
NCT06671587 · Sanofi
Recruiting, n=678P4
2026-08-21New trial registeredlixisenatideDose Ranging Study of the GLP-1 Agonist AVE0010 in Metformin-Treated Subjects With Type 2 Diabetes Mellitus
NCT00299871 · Sanofi
Completed, n=542P2
2026-08-21New trial registeredlixisenatideEfficacy and Safety of Insulin Glargine/Lixisenatide Fixed Combination Versus Insulin Glargine Alone on Top of Metformin in Type 2 Diabetic Patients
NCT01476475 · Sanofi
Completed, n=323P2
2026-08-21New trial registeredlixisenatideEfficacy and Safety of iGlarLixi Versus Standard of Care in a Real-world Adult China Population With Uncontrolled Type 2 Diabetes on Oral Agents
NCT07307235 · Shanghai Zhongshan Hospital
Recruiting, n=1,316P4
2026-08-21New trial registeredlixisenatideGLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Basal Insulin +/- Sulfonylurea (GETGOAL-L-ASIA)
NCT00866658 · Sanofi
Completed, n=311P3
2026-08-21New trial registeredlixisenatideFeasibility of Once/Daily Administered GLP/1 Receptoragonist (Lixisenatide) in Combination With Basal Insulin
NCT02168491 · Medical University of Vienna
Completed, n=10P3
2026-08-21New trial registeredlixisenatideEffect of Lixisenatide on Postprandial Lipid Profile in Obese Type 2 Diabetic Patients
NCT02274740 · Sanofi
Terminated, n=2P2
2026-08-21New trial registeredlixisenatideGLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Metformin
NCT00763451 · Sanofi
Completed, n=484P3
2026-08-21New trial registeredlixisenatideEffect of Lixisenatide on Postprandial Plasma Glucose Compared to Sitagliptin in Combination With Insulin Glargine
NCT02200991 · Sanofi
Completed, n=136P4
2026-08-21New trial registeredlixisenatideRemission Evaluation of a Metabolic Intervention for Type 2 Diabetes With IGlarLixi
NCT03130426 · Population Health Research Institute
Completed, n=161P3
2026-08-21New trial registeredlixisenatideA Study to Investigate Safety and Efficacy of iGlarLixi in Adult Patients With Type 2 Diabetes Mellitus
NCT06716424 · Sanofi
Completed, n=105P4
2026-08-21New trial registeredlixisenatideEffect of LIXIsenatide on the Renal System
NCT02276196 · Amsterdam UMC, location VUmc
Completed, n=40P4
2026-08-21New trial registeredlixisenatideAssessment of the Efficacy and Safety of Lixisenatide in Patients With Type 2 Diabetes Insufficiently Controlled With Basal Insulin +/- Metformin
NCT01632163 · Sanofi
Completed, n=447P3
2026-08-21New trial registeredlixisenatideComparison of Lixisenatide Injected Prior to the Main Meal of the Day Versus Prior to Breakfast in Type 2 Diabetic Patients on Metformin
NCT01517412 · Sanofi
Completed, n=451P3
2026-08-21New trial registeredaleniglipronAleniglipron Phase 2 in Type 2 Diabetes Mellitus
NCT07400588 · Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics
Active, not recruiting, n=58P2
2026-08-21New trial registeredaleniglipronAleniglipron Phase 2 Body Composition Study
NCT07169942 · Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics
Active, not recruiting, n=71P2
2026-08-21New trial registeredaleniglipronA Phase 2b, Dose-range Finding Study of the Efficacy and Safety of Multiple Doses of Aleniglipron (GSBR-1290) in Participants Living With Obesity or Overweight With at Least One Weight-related Comorbidity
NCT06693843 · Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics
Completed, n=230P2
2026-08-21New trial registeredaleniglipronA Dose-Range Study of Aleniglipron (GSBR-1290) in Participants Living With Obesity or Overweight With at Least One Weight-related Comorbidity
NCT06703021 · Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics
Completed, n=85P2
2026-08-21New trial registeredolatorepatideStudy of Olatorepatide in Adult Participants Living With Overweight or Obesity Without Diabetes
NCT07685808 · Regeneron Pharmaceuticals
Recruiting, n=360P2
2026-08-21New trial registeredolatorepatideStudy of Olatorepatide in Adult Participants Living With Overweight or Obesity in the US
NCT07431086 · Regeneron Pharmaceuticals
Active, not recruiting, n=120P2
2026-08-21New trial registeredalbiglutideAlbiglutide Versus Placebo in Insulin-treated Subjects With New-onset Type 1 Diabetes Mellitus
NCT02284009 · GlaxoSmithKline
Completed, n=67P2
2026-08-21New trial registeredalbiglutideDose Ranging Study of Albiglutide in Japanese Subjects
NCT01098461 · GlaxoSmithKline
Completed, n=215P2
2026-08-21New trial registeredalbiglutideA Study to Evaluate Pharmacokinetics, Safety and Efficacy of Albiglutide in Pediatric Subjects With Type 2 Diabetes Mellitus
NCT03015519 · GlaxoSmithKline
WithdrawnP3
2026-08-21New trial registeredalbiglutideSafety and Efficacy Study of Albiglutide in Type 2 Diabetes
NCT00849017 · GlaxoSmithKline
Completed, n=309P3
2026-08-21New trial registeredalbiglutideEffect of Albiglutide, When Added to Standard Blood Glucose Lowering Therapies, on Major Cardiovascular Events in Subjects With Type 2 Diabetes Mellitus
NCT02465515 · GlaxoSmithKline
Completed, n=9,463P4
2026-08-21New trial registeredalbiglutideA Study to Determine the Long Term Safety and Efficacy of Albiglutide in Combination With Oral Monotherapy Antihyperglycemic Medications in Japanese Patients With Type 2 Diabetes Mellitus
NCT01777282 · GlaxoSmithKline
Completed, n=374P3
2026-08-21New trial registeredalbiglutideAlbiglutide Glucose Clamp Study in Subjects With Type 2 Diabetes
NCT01475734 · GlaxoSmithKline
Completed, n=44P2
2026-08-21New trial registeredalbiglutideSafety and Efficacy of Albiglutide in Type 2 Diabetes
NCT00849056 · GlaxoSmithKline
Completed, n=310P3
2026-08-21New trial registeredalbiglutideIn-patient Study With GSK716155 In Patients With Type 2 Diabetes Mellitus
NCT00354536 · GlaxoSmithKline
Completed, n=60P2
2026-08-21New trial registeredalbiglutideExtension to Study 200952 to Evaluate the Long-term Safety, Tolerability and Pharmacodynamics of Albiglutide Liquid Drug Product in Type 2 Diabetes Mellitus Subjects
NCT02750930 · GlaxoSmithKline
Terminated, n=8P4
2026-08-21New trial registeredalbiglutidePharmacokinetics/Pharmacodynamics of Albiglutide
NCT01357889 · GlaxoSmithKline
Completed, n=283P2
2026-08-21New trial registeredalbiglutideSafety and Efficacy Study of Albiglutide Liquid Drug Product in Type 2 Diabetes Mellitus
NCT02683746 · GlaxoSmithKline
Completed, n=308P3
2026-08-21New trial registeredalbiglutideAlbiglutide Versus Placebo Added-on to Basal-Bolus Insulin Therapy in Subjects With Type 2 Diabetes Mellitus
NCT02229240 · GlaxoSmithKline
WithdrawnP3
2026-08-21New trial registeredalbiglutideA Study Evaluating the Effect of Albiglutide on Gallbladder Emptying in Healthy Subjects
NCT02496221 · GlaxoSmithKline
Completed, n=20P4
@glp1briefing